These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 19076359

  • 21. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.
    Hadac EM, Ji Z, Pinon DI, Henne RM, Lybrand TP, Miller LJ.
    J Med Chem; 1999 Jun 17; 42(12):2105-11. PubMed ID: 10377216
    [Abstract] [Full Text] [Related]

  • 22. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
    Gigoux V, Maigret B, Escrieut C, Silvente-Poirot S, Bouisson M, Fehrentz JA, Moroder L, Gully D, Martinez J, Vaysse N, Fourmy AD.
    Protein Sci; 1999 Nov 17; 8(11):2347-54. PubMed ID: 10595537
    [Abstract] [Full Text] [Related]

  • 23. Constitutive and agonist-dependent homo-oligomerization of the thyrotropin-releasing hormone receptor. Detection in living cells using bioluminescence resonance energy transfer.
    Kroeger KM, Hanyaloglu AC, Seeber RM, Miles LE, Eidne KA.
    J Biol Chem; 2001 Apr 20; 276(16):12736-43. PubMed ID: 11278883
    [Abstract] [Full Text] [Related]

  • 24. Melanocortin receptors form constitutive homo- and heterodimers.
    Mandrika I, Petrovska R, Wikberg J.
    Biochem Biophys Res Commun; 2005 Jan 14; 326(2):349-54. PubMed ID: 15582585
    [Abstract] [Full Text] [Related]

  • 25. Applications of fluorescence in the characterization of the ligand-binding domain and activation of the cholecystokinin receptor.
    Harikumar KG, Miller LJ.
    Pharmacol Toxicol; 2002 Dec 14; 91(6):286-9. PubMed ID: 12688370
    [Abstract] [Full Text] [Related]

  • 26. Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.
    Harikumar KG, Akgün E, Portoghese PS, Miller LJ.
    J Med Chem; 2010 Apr 08; 53(7):2836-42. PubMed ID: 20235611
    [Abstract] [Full Text] [Related]

  • 27. Mutation of Asn-391 within the conserved NPXXY motif of the cholecystokinin B receptor abolishes Gq protein activation without affecting its association with the receptor.
    Galés C, Kowalski-Chauvel A, Dufour MN, Seva C, Moroder L, Pradayrol L, Vaysse N, Fourmy D, Silvente-Poirot S.
    J Biol Chem; 2000 Jun 09; 275(23):17321-7. PubMed ID: 10748160
    [Abstract] [Full Text] [Related]

  • 28. Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits galphaq protein signaling but not ERK activation.
    Hansen JL, Theilade J, Haunsø S, Sheikh SP.
    J Biol Chem; 2004 Jun 04; 279(23):24108-15. PubMed ID: 15056658
    [Abstract] [Full Text] [Related]

  • 29. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
    Escrieut C, Gigoux V, Archer E, Verrier S, Maigret B, Behrendt R, Moroder L, Bignon E, Silvente-Poirot S, Pradayrol L, Fourmy D.
    J Biol Chem; 2002 Mar 01; 277(9):7546-55. PubMed ID: 11724786
    [Abstract] [Full Text] [Related]

  • 30. Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor.
    Harikumar KG, Puri V, Singh RD, Hanada K, Pagano RE, Miller LJ.
    J Biol Chem; 2005 Jan 21; 280(3):2176-85. PubMed ID: 15537636
    [Abstract] [Full Text] [Related]

  • 31. Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors.
    Harikumar KG, Morfis MM, Lisenbee CS, Sexton PM, Miller LJ.
    Mol Pharmacol; 2006 Jan 21; 69(1):363-73. PubMed ID: 16244179
    [Abstract] [Full Text] [Related]

  • 32. Insights into the molecular basis of ligand binding by the cholecystokinin receptor.
    Miller LJ, Ding XQ.
    Pancreatology; 2001 Jan 21; 1(4):336-42. PubMed ID: 12120212
    [Abstract] [Full Text] [Related]

  • 33. Real-time analysis of agonist-induced activation of protease-activated receptor 1/Galphai1 protein complex measured by bioluminescence resonance energy transfer in living cells.
    Ayoub MA, Maurel D, Binet V, Fink M, Prézeau L, Ansanay H, Pin JP.
    Mol Pharmacol; 2007 May 21; 71(5):1329-40. PubMed ID: 17267663
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling.
    Ji Z, Hadac EM, Henne RM, Patel SA, Lybrand TP, Miller LJ.
    J Biol Chem; 1997 Sep 26; 272(39):24393-401. PubMed ID: 9305898
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.